53.73
3.45%
-1.92
Pre-market:
54.48
0.75
+1.40%
CRISPR Therapeutics AG stock is currently priced at $53.73, with a 24-hour trading volume of 1.24M.
It has seen a -3.45% decreased in the last 24 hours and a -24.41% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $56.31 pivot point. If it approaches the $52.56 support level, significant changes may occur.
Previous Close:
$55.65
Open:
$53.98
24h Volume:
1.24M
Market Cap:
$4.56B
Revenue:
$170.10M
Net Income/Loss:
$-153.61M
P/E Ratio:
-12.02
EPS:
-4.47
Net Cash Flow:
$-272.35M
1W Performance:
-4.33%
1M Performance:
-24.41%
6M Performance:
+37.14%
1Y Performance:
+8.70%
CRISPR Therapeutics AG Stock (CRSP) Company Profile
Name
CRISPR Therapeutics AG
Sector
Industry
Phone
41 41 561 3277
Address
Baarerstrasse 14, Zug
CRISPR Therapeutics AG Stock (CRSP) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
Dec-11-23 | Downgrade | TD Cowen | Market Perform → Underperform |
Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Sep-27-23 | Initiated | Mizuho | Buy |
Aug-17-23 | Upgrade | Citigroup | Neutral → Buy |
May-30-23 | Initiated | William Blair | Outperform |
Apr-13-23 | Initiated | Cantor Fitzgerald | Overweight |
Mar-21-23 | Initiated | Bernstein | Mkt Perform |
Mar-17-23 | Initiated | Bryan Garnier | Buy |
Mar-07-23 | Initiated | Robert W. Baird | Neutral |
Oct-11-22 | Initiated | Morgan Stanley | Underweight |
Aug-09-22 | Downgrade | Barclays | Overweight → Equal Weight |
Jun-23-22 | Downgrade | Evercore ISI | Outperform → In-line |
Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
Apr-28-22 | Initiated | Credit Suisse | Neutral |
Dec-07-21 | Initiated | Cowen | Market Perform |
Oct-19-21 | Initiated | SVB Leerink | Outperform |
Jun-14-21 | Upgrade | Citigroup | Sell → Neutral |
Apr-21-21 | Upgrade | Jefferies | Hold → Buy |
Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
Dec-10-20 | Reiterated | Chardan Capital Markets | Buy |
Dec-10-20 | Downgrade | Jefferies | Buy → Hold |
Dec-10-20 | Reiterated | Needham | Buy |
Dec-07-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
Oct-05-20 | Initiated | BofA Securities | Buy |
Jul-28-20 | Reiterated | Needham | Buy |
Jul-14-20 | Initiated | SunTrust | Buy |
Jun-15-20 | Reiterated | Canaccord Genuity | Buy |
Mar-05-20 | Initiated | Stifel | Hold |
Feb-03-20 | Downgrade | Evercore ISI | Outperform → In-line |
Nov-19-19 | Upgrade | William Blair | Mkt Perform → Outperform |
Nov-12-19 | Upgrade | Oppenheimer | Perform → Outperform |
Aug-01-19 | Initiated | Jefferies | Buy |
Jul-26-19 | Initiated | Canaccord Genuity | Buy |
Jun-10-19 | Initiated | ROTH Capital | Buy |
Apr-12-19 | Initiated | Evercore ISI | Outperform |
Mar-14-19 | Initiated | William Blair | Mkt Perform |
Jan-28-19 | Downgrade | Goldman | Buy → Neutral |
Jan-22-19 | Downgrade | Citigroup | Neutral → Sell |
View All
CRISPR Therapeutics AG Stock (CRSP) Latest News
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
The Motley Fool
Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?
The Motley Fool
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why
Zacks Investment Research
CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
GlobeNewswire Inc.
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update
Seeking Alpha
Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now?
Zacks Investment Research
CRISPR Therapeutics AG Stock (CRSP) Financials Data
CRISPR Therapeutics AG (CRSP) Revenue 2024
CRSP reported a revenue (TTM) of $170.10 million for the quarter ending June 30, 2023, a +1,207% rise year-over-year.
CRISPR Therapeutics AG (CRSP) Net Income 2024
CRSP net income (TTM) was -$153.61 million for the quarter ending December 31, 2023, a +76.37% increase year-over-year.
CRISPR Therapeutics AG (CRSP) Cash Flow 2024
CRSP recorded a free cash flow (TTM) of -$272.35 million for the quarter ending December 31, 2023, a +48.90% increase year-over-year.
CRISPR Therapeutics AG (CRSP) Earnings per Share 2024
CRSP earnings per share (TTM) was -$1.93 for the quarter ending December 31, 2023, a +76.94% growth year-over-year.
CRISPR Therapeutics AG Stock (CRSP) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Kulkarni Samarth | Chief Executive Officer |
Apr 15 '24 |
Option Exercise |
19.12 |
19,582 |
374,408 |
227,704 |
Kulkarni Samarth | Chief Executive Officer |
Apr 15 '24 |
Sale |
59.91 |
19,582 |
1,173,232 |
208,122 |
Kulkarni Samarth | Chief Executive Officer |
Mar 15 '24 |
Option Exercise |
19.12 |
20,000 |
382,400 |
228,122 |
Kulkarni Samarth | Chief Executive Officer |
Mar 15 '24 |
Sale |
72.48 |
20,000 |
1,449,628 |
208,122 |
Prasad Raju | Chief Financial Officer |
Mar 15 '24 |
Sale |
72.69 |
3,524 |
256,160 |
6,476 |
Kulkarni Samarth | Chief Executive Officer |
Mar 12 '24 |
Sale |
74.44 |
4,583 |
341,159 |
208,122 |
KASINGER JAMES R. | General Counsel and Secretary |
Mar 12 '24 |
Sale |
74.44 |
1,146 |
85,308 |
61,174 |
Kulkarni Samarth | Chief Executive Officer |
Mar 11 '24 |
Sale |
78.26 |
9,802 |
767,105 |
203,705 |
KASINGER JAMES R. | General Counsel and Secretary |
Mar 11 '24 |
Sale |
78.26 |
2,801 |
219,206 |
60,070 |
Kulkarni Samarth | Chief Executive Officer |
Feb 20 '24 |
Sale |
79.67 |
6,370 |
507,498 |
194,257 |
About CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient. The company is also developing CTX101, a donor-derived gene-edited allogeneic CAR-T therapy targeting CD19-positive malignancies. In addition, it is developing earlier stage allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; hemoglobinopathies to treat other diseases, including Hurler Syndrome and severe combined immunodeficiency disease; programs that are in preclinical development for indications, including glycogen storage disease Ia and hemophilia; and programs targeting diseases of organ systems outside the liver, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use therapeutics. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer; and with the ViaCyte, Inc. for designing allogeneic cell therapies derived from gene edited human stem cells for use in the treatment of diabetes type 1, diabetes type 2, and insulin dependent diabetes. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Cap:
|
Volume (24h):